Treatment of mixed features in bipolar disorder

CNS Spectrums

Volumn 22, Issue 2, 2017, Pages 141-146

  Rosenblat, Joshua D ^a   Mcintyre, Roger S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; bipolar disorder; DSM 5; mixed episode; mixed features; mixed states; mood stabilizers

Indexed keywords

ASENAPINE; FLUOXETINE PLUS OLANZAPINE; LURASIDONE; OLANZAPINE; PLACEBO; QUETIAPINE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ANTIDEPRESSANT ACTIVITY; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL GLOBAL IMPRESSION FOR BIPOLAR DISORDER OVERALL SEVERITY SCORE; DEPRESSION ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-5; HUMAN; HYPOMANIA; MAJOR DEPRESSION; MANIA; MANIA ASSESSMENT; MANIA RATING SCALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; REVIEW; SYSTEMATIC REVIEW; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; CLASSIFICATION; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; PSYCHOLOGY;

BIPOLAR DISORDER; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS;

EID: 84987602356     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852916000547     Document Type: Review

References (28)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Swann AC, Lafer B, Perugi G, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013; 170(1): 31-42.
4. Castle DJ. Bipolar mixed states: still mixed up?. Curr Opin Psychiatry. 2014; 27(1): 38-42.
5. Benvenuti A, Miniati M, Callari A, Giorgi Mariani M, Mauri M, DellOsso L. Mood spectrum model: evidence reconsidered in the light of DSM-5. World J Psychiatry. 2015; 5(1): 126-137.
6. Kessing LV. The prevalence of mixed episodes during the course of illness in bipolar disorder. Acta Psychiatr Scand. 2008; 117(3): 216-224.
7. McIntyre RS, Soczynska JK, Cha DS, et al. The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord. 2015; 172: 259-264.
8. Verdolini N, Agius M, Ferranti L, Moretti P, Piselli M, Quartesan R. The state of the art of the DSM-5 "with mixed features" specifier. The Scientific World Journal. 2015; 2015: 757258.
9. Shim IH, Woo YS, Jun TY, Bahk WM. Mixed-state bipolar I and II depression: time to remission and clinical characteristics. J Affect Disord. 2014; 152-154: 340-346.
10. Undurraga J, Baldessarini RJ, Valenti M, Pacchiarotti I, Vieta E. Suicidal risk factors in bipolar I and II disorder patients. J Clin Psychiatry. 2012; 73(6): 778-782.
11. Shim IH, Woo YS, Bahk WM. Prevalence rates and clinical implications of bipolar disorder "with mixed features" as defined by DSM-5. J Affect Disord. 2015; 173: 120-125.
12. Popovic D, Vieta E, Azorin JM, et al. Suicide attempts in major depressive episode: evidence from the BRIDGE-II-Mix study. Bipolar Disord. 2015; 17(7): 795-803.
13. Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry. 2009; 70(10): 1424-1431.
14. Patkar A, Gilmer W, Pae CU, et al. A 6 week randomized doubleblind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012; 7(4): e34757.
15. Pae CU, Patkar AA, Gilmer W, Holtzman N, Thommi SB, Ghaemi SN. Predictors of response to ziprasidone: results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state. Pharmacopsychiatry. 2012; 45(4): 152-155.
16. Tohen M, Kanba S, McIntyre RS, Fujikoshi S, Katagiri H. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord. 2014; 164: 57-62.
17. McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebocontrolled trial. J Clin Psychiatry. 2015; 76(4): 398-405.
18. McIntyre RS, Tohen M, Berk M, Zhao J, Weiller E. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. J Affect Disord. 2013; 150(2): 378-383.
19. Tohen M, McIntyre RS, Kanba S, Fujikoshi S, Katagiri H. Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5. J Affect Disord. 2014; 168: 136-141.
20. Suppes T, Ketter TA, Gwizdowski IS, et al. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo. J Affect Disord. 2013; 150(1): 37-43.
21. Perlis RH, Cusin C, Fava M. Proposed DSM-5 mixed features are associated with greater likelihood of remission in out-patients with major depressive disorder. Psychol Med. 2014; 44(7): 1361-1367.
22. Suppes T, Silva R, Cucchiaro J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016; 173(4): 400-407.
23. McIntyre RS. 2015 Florida Best Practice PsychotherapeuticMedication Guidelines for Adults. 2015. http://medicaidmentalhealth.org/View Guideline.cfm?GuidelineID=97. Accessed April 20, 2016.
24. Fagiolini A, Coluccia A, Maina G, et al. Diagnosis, epidemiology and management of mixed states in bipolar disorder. CNS Drugs. 2015; 29(9): 725-740.
25. Fountoulakis KN, Kontis D, Gonda X, Siamouli M, Yatham LN. Treatment of mixed bipolar states. Int J Neuropsychopharmacol. 2012; 15(7): 1015-1026.
26. McIntyre RS, Yoon J. Efficacy of antimanic treatments in mixed states. Bipolar Disord. 2012; 14(Suppl 2): 22-36.
27. Muralidharan K, Ali M, Silveira LE, et al. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-Analysis of placebo-controlled trials. J Affect Disord. 2013; 150(2): 408-414.
28. McElroy SL, Martens BE, Creech RS, et al. Randomized, doubleblind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-To-severe hypomania or mild mania. J Clin Psychiatry. 2010; 71(5): 557-565.